Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Arovella Therapeutics Limited (ALA) Share Price & Analysis

ALA Stock Chart & Stats

A$0.05A$0.00(3.92%)
At close: 4:00 PM GMT+11
AU$0.05AU$0.055AU$0.06AU$0.0653 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 0.05 - AUD 0.06
52-Week Range
AUD 0.05 - AUD 0.10
Previous Close
AUD 0.05
Volume
855.69K
Average Volume (3M)
836.12K
Market Cap
AUD 64.07M
Enterprise Value
AUD 60.24M
Total Cash (Recent Filing)
AUD 14.35M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
―
Beta
1.50
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Minimal Leverage

Minimal leverage reduces interest burden and near-term refinancing pressure, giving Arovella greater financial flexibility while it advances its therapies. Although the company remains funding-dependent, a debt-light balance sheet lowers the risk that existing obligations will constrain research investment or recovery options.

Positive Net Asset Position

Assets exceeding liabilities and positive equity provide a stronger solvency base than many highly leveraged development-stage businesses. This cushion can support continued operations and strategic flexibility over the coming quarters, even though recurring losses and changing equity levels show that capital is still being consumed.

Focused Cell Therapy Platform

Arovella has a focused biotechnology strategy centered on engineered immune-cell approaches and CAR-related technologies intended to improve targeting and potency. Concentration on a defined therapeutic platform can help align research resources and build differentiated capabilities as programs progress through development.

Bears Say

No Scalable Commercial Revenue

The absence of meaningful commercial revenue indicates that Arovella has not yet established a scalable operating base. Without product sales to fund activities, the company remains dependent on development progress and external capital, making financial performance vulnerable to continued delays or unsuccessful programs.

Persistent Operating Losses

Recurring operating and net losses show that current activities do not yet generate sustainable earnings or self-funded growth. Continued losses can reduce equity over time and require additional financing, while the lack of improving margins limits evidence that profitability will emerge in the next several quarters.

Ongoing Cash Burn

Sustained negative operating cash flow means Arovella must continue relying on external funding to maintain research and development. Persistent burn can consume its capital base and restrict strategic choices, even with minimal debt, particularly if clinical or development timelines extend.

Arovella Therapeutics Limited News

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.05 and its highest was AU$0.10 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$64.07M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Sep 02, 2026. The company reported -AU$0.004 earnings per share for the quarter.
Is Arovella Therapeutics Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology